Edmond DE Rothschild Holding S.A. Has $43.58 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Edmond DE Rothschild Holding S.A. raised its position in Zoetis Inc. (NYSE:ZTS) by 82.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 267,482 shares of the company’s stock after acquiring an additional 120,732 shares during the period. Edmond DE Rothschild Holding S.A. owned about 0.06% of Zoetis worth $43,581,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Norges Bank acquired a new position in shares of Zoetis in the fourth quarter valued at $824,321,000. Wellington Management Group LLP raised its stake in shares of Zoetis by 78.5% in the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock valued at $1,133,755,000 after buying an additional 3,059,255 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Zoetis during the 4th quarter worth about $196,651,000. Polen Capital Management LLC lifted its holdings in shares of Zoetis by 17.5% during the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock worth $1,219,237,000 after acquiring an additional 1,116,541 shares during the period. Finally, Amundi boosted its position in shares of Zoetis by 46.2% during the 4th quarter. Amundi now owns 2,748,719 shares of the company’s stock valued at $453,355,000 after acquiring an additional 867,993 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 in the last ninety days. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on ZTS. Piper Sandler raised their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Morgan Stanley lowered their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Finally, UBS Group started coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $215.90.

Zoetis Stock Down 1.2 %

Shares of NYSE:ZTS opened at $163.03 on Monday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The company’s 50-day moving average price is $166.40 and its two-hundred day moving average price is $174.44. The firm has a market cap of $73.00 billion, a P/E ratio of 29.80, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. As a group, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.23%. Zoetis’s dividend payout ratio is presently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.